About ADC Biotechnology
ADC Biotechnology is a Healthcare company based in Saint Asaph (United Kingdom) founded in 2010, and was acquired by Sterling Pharma Solutions in April 2021. Developer of antibody drug conjugate (ADC). ADC Biotechnology has raised $16.16 million across 7 funding rounds from investors including Development Bank of Wales, Downing and Maven Capital Partners. The company has 38 employees. The company was acqui-hired. ADC Biotechnology offers products and services including Prediksi Macau and Live Draw Macau. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is ADC Biotechnology Ltd.
Company details
ADC Bio is developing antibody-drug conjugate (ADC). Its proprietary technology called Lock-Release involves conjugation of proteins that are immobilised on solid supports and delivers key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. It also provides technical services including conjugation to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.
- Headquarters Saint Asaph, United Kingdom
- Employees 38
- Stage Acquired
- SectorsHealthcare
- Website adcbio.com
- Social LinkedIn X
- Acquired by Sterling Pharma Solutions (Apr 2021)
- Legal Name Adc Biotechnology Ltd
- Annual Revenue$2.11 M (USD)-2as on Apr 30, 2020
- Total Equity Funding$16.16M (USD)
in 7 rounds
- InvestorsDevelopment Bank of Wales
& 10 more
- Employee Count38
- Acquired bySterling Pharma Solutions
(Apr 2021)
Products & Services of ADC Biotechnology
ADC Biotechnology offers a comprehensive portfolio of products and services, including Prediksi Macau and Live Draw Macau.
Provides forecasts for Macau lottery numbers
Delivers real-time lottery draw updates
Funding Insights of ADC Biotechnology
ADC Biotechnology has successfully raised a total of $16.16M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.16M
- Total Rounds 7
- Investors Count 11
All 7 funding rounds of ADC Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | Series A | – | Sterling Pharma Solutions | – | |
| Nov 2018 | $3.23M | Series A | – | Maven Capital Partners, Seneca | – |
| Apr 2018 | $1.59M | Series A | – | Downing, BioScience Managers | – |
| Sep 2017 | $10.8M | Series A | – | Maven Capital Partners | |
| Dec 2011 | $160,437 | Grant | – | – | |
| Dec 2011 | $540,501 | Seed | – | Finance Wales, Acceleris Capital | – |
| Sep 2010 | Seed | – | – |
11 investors in total: 11 institutional.
Investors in ADC Biotechnology
ADC Biotechnology has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Development Bank of Wales, Downing and Maven Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Inheritance tax relief, funds, and bonds are provided across sectors. | 1986 | downing.co.uk | London, United Kingdom | |
BioScience Managers is engaged in healthcare investment and innovation. | biosciencemanagers.com | Melbourne, Australia | ||
Multiple sectors are targeted for private equity investments. | 2005 | mavencp.com | Birmingham, United Kingdom | |
Provider of equity funding and business & property development loans | 2001 | developmentbank.wales | Wrexham, United Kingdom | |
Contract development, manufacturing, and analytical services for APIs are offered. | 2016 | sterlingpharmasolutions.com | Dudley, United Kingdom | |
Seneca Partners is engaged in tax-advantaged investment services. | senecapartners.co.uk | Haydock, United Kingdom | ||
Sustainable business finance is provided for companies in Wales. | financewales.co.uk | Wrexham, United Kingdom | ||
Government services for Wales are delivered through public administration. | 1999 | gov.wales | Cardiff, United Kingdom | |
Provides expert VC fundraising and advisory services for ambitious tech founders. | 2000 | acceleris.com | Manchester, United Kingdom | |
Local government services are provided by Denbighshire County Council. | denbighshire.gov.uk | Ruthin, United Kingdom |
Investor details for ADC Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ADC Biotechnology
4 dated milestones of ADC Biotechnology across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ADC Biotechnology is founded.
- Funding First funding round.
- Funding Latest funding round, Series A,.
- Exit Acquired by Sterling Pharma Solutions.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ADC Biotechnology (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adc Biotechnology
Complete news archive for ADC Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADC Biotechnology
ADC Biotechnology was founded in 2010.
ADC Biotechnology is headquartered in Saint Asaph, United Kingdom. It is registered at Saint Asaph, Denbighshire, United Kingdom.
ADC Biotechnology is a funded company, having raised a total of $16.16M across 7 funding rounds to date.
ADC Biotechnology has 38 employees.
Annual revenue of ADC Biotechnology is $2.11M as on Apr 30, 2020.
ADC Bio is developing antibody-drug conjugate (ADC). Its proprietary technology called Lock-Release involves conjugation of proteins that are immobilised on solid supports and delivers key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. It also provides technical services including conjugation to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.
ADC Biotechnology offers Prediksi Macau and Live Draw Macau.
ADC Biotechnology has 11 investors. Key investors include Development Bank of Wales, Downing, Maven Capital Partners, Sterling Pharma Solutions, and Welsh Government.
ADC Biotechnology operates through Adc Biotechnology Ltd.
Yes. ADC Biotechnology was acquired by Sterling Pharma Solutions in April 2021.